U.S. Markets closed

Rosetta Genomics Ltd. (ROSG)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.95-0.08 (-3.94%)
At close: 4:00PM EDT
People also watch
RXIIPSTICLSNOPXACYCC

Rosetta Genomics Ltd.

10 Plaut Street
Science Park
Rehovot 76706
Israel
972 73 222 0700
http://www.rosettagx.com

SectorHealthcare
IndustryMedical Laboratories & Research
Full Time Employees86

Key Executives

NameTitlePayExercisedAge
Mr. Kenneth A. BerlinChief Exec. Officer and Pres533kN/A53
Mr. Ron Kalfus CPAChief Financial Officer242.05kN/A43
Mr. Oded Biran Adv.Gen. Counsel and Sec.106.87kN/A38
Dr. Eti Meiri Ph.D.VP of Research125.48kN/A49
Ms. Ana C. Ward Esq., M.S.,M.B.A.Exec. VP of Legal and Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company’s microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

Corporate Governance

Rosetta Genomics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.